Contributing to Global Healthcare Through Innovative Nanoparticle DDS Pharmaceutical Development

We offer next-generation cancer treatments using immunotherapy technology based on hyaluronic acid.

Hyaluronic Acid Nanogel[Sonanos™] – Paving the Future of Cancer Immunotherapy

By harnessing the full potential of hyaluronic acid nanogel (Sonanos™)—a cutting-edge excipient—we aim to transform the future of cancer treatment.

Hyaluronic acid nanogel encapsulates large amounts of APIs and enhances solubility to maximize therapeutic efficacy. Moreover, efficient drug delivery to lymph nodes and direct uptake by antigen-presenting cells (especially cDC1) dramatically improves cancer immunotherapy outcomes.

We welcome inquiries regarding feasibility study, partnerships and alliances at any time. For those who contact us, we are pleased to provide non-confidential brochure including detailed data.

Contact Us

A Novel Solution in Cancer Immunotherapy

Three Key Features of Hyaluronic Acid Nanogel

Drug Delivery: Hyaluronic acid nanogel self-assembles into nanoparticles that efficiently deliver therapeutic agents to immune cells.
Immune Activation: By activating T cells and other immune cells, hyaluronic acid nanogel strengthens the body’s ability to attack cancer cells.
Safety: Because it is based on hyaluronic acid, it offers excellent biocompatibility and is expected to have fewer side effects.

Team

Our mission is to provide groundbreaking therapies to patients suffering from disease.

 

CEO&Co-Founder　Ph.D　中井 貴士／Nakai Takashi
After earning a master’s degree at Kyoto University’s Graduate School of Engineering, he conducted antibody and DDS research at Chugai Pharmaceutical. While at Tokyo Medical and Dental University, he invented hyaluronic acid nanogel (Sonanos™) and earned a Ph.D. He later joined Asahi Kasei to commercialize the nanogel and led clinical trials for a cancer vaccine in collaboration with Mie University.

COO&Co-Founder　黒澤 丈朗 ／KUROSAWA TAKERO

After a master’s degree from National Taiwan University,  University of Bordeaux, and the Graduate School of Agro-Biomedical Science at University of Tsukuba, joined to BluePass Capital as an analyst. Later, provided strategic consulting services for enhancing corporate value to private equity (PE) fund portfolio companies at Prored Partners. Subsequently, at Asahi Kasei Corporation, managed the global reaching of Sonanos™ as a business development, playing a variety of role in launching DRG.

Scientific Advisor　Ph.D, MD　宮原 慶裕/Yoshihiro Miyahara 

Professor at the Department of Personalized Cancer Immunotherapy in Mie University.

Scientific Advisor　Ph.D, PhC 百瀬 文康／Momose Fumiyasu

Assistant professor at the Department of Personalized Cancer Immunotherapy in Mie University.

Company Overview

 

Company Name  　DiveRadGel 株式会社

English version   　DiveRadGel Co., Ltd.

Representative　　CEO:Takashi Nakai

Headquarters　　　Ginza, Chuo-ku, Tokyo

Establishment　　　June 10, 2024

Capital　　　　　　  2 million yen

Fiscal Year End　　 May